Your Medication Isn't Working (or Making You Sick). Your Genes May Be Why.

Your CYP2D6 gene encodes an enzyme responsible for breaking down roughly 25% of all medications in clinical use. This includes antidepressants (many SSRIs), opioid painkillers, beta-blockers, and codeine. If this enzyme works normally, medications move through your system at the right pace. Your brain and body have time to respond therapeutically before the drug is cleared.

Variants in CYP2D6 can make you a poor metabolizer, meaning your copy of the enzyme is slow or nonfunctional. Approximately 7-10% of people with European ancestry carry poor metabolizer variants. If you’re a poor metabolizer of, say, sertraline or tramadol, the drug accumulates in your bloodstream because your body can’t clear it fast enough, causing side effects at standard doses that would be therapeutic for someone else.

You might experience tremors, nausea, dizziness, or cognitive fogginess on a dose your doctor expected to help. The medication isn’t wrong. Your enzyme is slow. A dose reduction of 25-50% might eliminate all side effects while maintaining benefit.

Your CYP2C19 gene encodes an enzyme that metabolizes clopidogrel (Plavix), a blood thinner prescribed after heart attacks and stent placement. It also metabolizes many antidepressants and proton pump inhibitors (acid reflux medications). The critical issue is with clopidogrel: it’s a prodrug, meaning your body must convert it into its active form in order for it to work.

Poor metabolizers of CYP2C19 carry variants like *2 or *3, found in roughly 2-15% of the population depending on ancestry. If you’re a poor metabolizer, your body cannot convert clopidogrel into its active antiplatelet form, meaning the medication provides almost no blood-thinning benefit even though you’re taking it regularly. This puts you at risk of stent thrombosis or heart attack despite being on the medication.

Conversely, ultra-rapid metabolizers clear the drug so quickly they may experience elevated bleeding risk. Standard dosing assumes an average metabolizer. If you’ve had a stent placed and your cardiologist is unaware of your CYP2C19 status, you may be receiving ineffective or excessively risky medication.

Your CYP2C9 gene encodes an enzyme responsible for metabolizing warfarin, a blood thinner prescribed for atrial fibrillation and clotting disorders. This same enzyme also processes NSAIDs like ibuprofen and naproxen. Variants in CYP2C9 (*2 and *3) significantly slow enzyme activity, creating a critical dosing problem.

Roughly 5-10% of people with European ancestry are poor metabolizers of CYP2C9 substrates. Poor metabolizers on standard warfarin doses accumulate the drug in their system, causing bleeding risk that standard INR monitoring may not catch quickly enough. Your doctor would typically start you on a dose calculated from clinical guidelines. If you’re a poor metabolizer, that dose may be too high from day one.

You might find that even small warfarin doses produce INR values (blood-thinning measurements) far higher than your doctor intended. You’d bleed more easily from minor cuts, experience unexpected bruising, or have nosebleeds. The medication is working, but far too aggressively because your body can’t clear it at the expected rate. Genetic testing allows your doctor to prescribe a dose tailored to your enzyme activity from the start.

Your VKORC1 gene encodes vitamin K epoxide reductase, an enzyme that recycles vitamin K in your body. Warfarin works by inhibiting this enzyme, preventing vitamin K recycling and thus reducing clotting factors. A common variant in VKORC1 (-1639G>A) alters how sensitive your body is to this inhibition.

Approximately 40% of people with European ancestry carry the A allele, which reduces vitamin K recycling efficiency even before warfarin is introduced. People with the A allele are exquisitely sensitive to warfarin and require substantially lower doses than those without it. Your body simply recycles vitamin K poorly, so blocking that pathway further creates rapid anticoagulation.

If your doctor prescribes a standard warfarin dose and you carry the VKORC1 A allele, you’ll rapidly become over-anticoagulated. You might experience spontaneous bruising, blood in your urine, or excessive bleeding from minor cuts before your INR is even checked. Genetic testing identifies you as a warfarin-sensitive individual so your doctor can start you on a lower dose from the beginning and adjust more conservatively.

Your SLCO1B1 gene encodes a transporter protein that actively moves statins from your bloodstream into your liver cells, where they work to lower cholesterol. This is a critical step: statins need to be inside liver cells to be effective. A variant in SLCO1B1 (rs4149056, the C allele) reduces this transporter’s activity.

Roughly 15% of the population carries the C allele, which impairs hepatic statin uptake. If you have this variant, statins don’t enter your liver cells efficiently, so they linger in your bloodstream at elevated concentrations, increasing your risk of muscle pain, weakness, and myopathy. Your liver isn’t getting the dose it needs, but your muscles and other tissues are getting too much.

You might experience unexplained muscle aches that seem to appear only after starting a statin. Your doctor orders muscle enzymes (CPK) and they’re normal, so the symptoms get dismissed as coincidence. But the muscle pain is real and directly caused by statin accumulation outside the liver. Genetic testing identifies you as someone who needs either a lower statin dose, a different statin class, or a non-statin cholesterol-lowering agent.

Your TPMT gene encodes thiopurine S-methyltransferase, an enzyme that metabolizes thiopurine drugs like azathioprine and 6-mercaptopurine. These medications are immunosuppressants prescribed for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and other autoimmune conditions. The enzyme’s job is to break down these drugs to safe levels inside your body.

Approximately 0.3% of the population (roughly 1 in 300 people) are poor metabolizers of TPMT, meaning they carry variants that nonfunctional or severely impaired copies of this enzyme. Poor metabolizers cannot clear thiopurine drugs efficiently, causing toxic metabolite accumulation in bone marrow and white blood cells, which can trigger severe bone marrow suppression and life-threatening infections.

If you’re a poor metabolizer and your doctor prescribes standard azathioprine or 6-mercaptopurine doses, you’ll rapidly develop severe bone marrow toxicity. Your white blood cell count crashes, leaving you vulnerable to infections. Your platelet count drops, causing unexpected bruising and bleeding. Genetic testing before starting thiopurines is standard of care because untested poor metabolizers can develop irreversible bone marrow damage within weeks of starting treatment.